K

Keymed Biosciences
2162

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
HK$13.61B
EV
HK$12.12B
Shares Outstanding
294.60M
Beta
-0.03

Wall Street View

Analyst Rating
BUY
Analyst Target Price
HK$56.40
P/E 2025E
-
P/Revenue 2025E
17.99x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Keymed Biosciences Inc.

gainify

K

Keymed Biosciences Inc.

2162

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD...

Sector

Healthcare

Industry

Biotechnology

CEO

Chen, Bo

Employees

1,258

IPO Date

2021-07-08

Headquarters

Building D2, No. 18 BioTown Middle Road, Tianfu International BioTown, Shuangliu District, Chengdu, Sichuan Province, 610219, China

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.